FY2025 Earnings Forecast for IPSC Issued By Chardan Capital

Century Therapeutics, Inc. (NASDAQ:IPSC) – Stock analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Century Therapeutics in a research report issued on Monday, March 24th. Chardan Capital analyst Y. Livshits forecasts that the company will earn ($0.33) per share for the year. Chardan Capital has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.61) per share. Chardan Capital also issued estimates for Century Therapeutics’ FY2026 earnings at ($0.64) EPS.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.02. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. The business had revenue of $4.18 million during the quarter, compared to the consensus estimate of $0.67 million.

A number of other research firms have also recently issued reports on IPSC. Guggenheim dropped their price objective on shares of Century Therapeutics from $12.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, March 21st. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Finally, Piper Sandler reduced their price objective on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating on the stock in a research report on Thursday, March 20th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Century Therapeutics has a consensus rating of “Buy” and a consensus target price of $5.00.

Century Therapeutics Trading Up 0.2 %

IPSC stock opened at $0.56 on Thursday. The firm has a 50-day moving average price of $0.72 and a 200-day moving average price of $1.14. Century Therapeutics has a 12 month low of $0.52 and a 12 month high of $4.43. The stock has a market capitalization of $47.84 million, a P/E ratio of -0.30 and a beta of 1.75.

Hedge Funds Weigh In On Century Therapeutics

Several large investors have recently modified their holdings of the business. Geode Capital Management LLC increased its holdings in Century Therapeutics by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 991,595 shares of the company’s stock valued at $1,002,000 after purchasing an additional 23,413 shares during the period. Jane Street Group LLC grew its position in shares of Century Therapeutics by 166.2% in the 4th quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock valued at $49,000 after buying an additional 29,992 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Century Therapeutics by 109.1% in the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock valued at $67,000 after buying an additional 34,466 shares during the period. Marshall Wace LLP bought a new position in shares of Century Therapeutics during the fourth quarter worth about $36,000. Finally, Barclays PLC lifted its stake in shares of Century Therapeutics by 283.6% in the third quarter. Barclays PLC now owns 61,945 shares of the company’s stock worth $106,000 after acquiring an additional 45,797 shares during the period. Institutional investors own 50.20% of the company’s stock.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.